1. Home
  2. ADAP vs NKSH Comparison

ADAP vs NKSH Comparison

Compare ADAP & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • NKSH
  • Stock Information
  • Founded
  • ADAP 2008
  • NKSH 1891
  • Country
  • ADAP United Kingdom
  • NKSH United States
  • Employees
  • ADAP N/A
  • NKSH N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • NKSH Major Banks
  • Sector
  • ADAP Health Care
  • NKSH Finance
  • Exchange
  • ADAP Nasdaq
  • NKSH Nasdaq
  • Market Cap
  • ADAP 212.3M
  • NKSH 182.9M
  • IPO Year
  • ADAP 2015
  • NKSH N/A
  • Fundamental
  • Price
  • ADAP $0.62
  • NKSH $30.87
  • Analyst Decision
  • ADAP Strong Buy
  • NKSH Strong Buy
  • Analyst Count
  • ADAP 4
  • NKSH 1
  • Target Price
  • ADAP $2.79
  • NKSH $38.00
  • AVG Volume (30 Days)
  • ADAP 2.3M
  • NKSH 14.4K
  • Earning Date
  • ADAP 11-13-2024
  • NKSH 10-24-2024
  • Dividend Yield
  • ADAP N/A
  • NKSH 4.92%
  • EPS Growth
  • ADAP N/A
  • NKSH N/A
  • EPS
  • ADAP N/A
  • NKSH 1.44
  • Revenue
  • ADAP $175,041,000.00
  • NKSH $43,450,000.00
  • Revenue This Year
  • ADAP $204.91
  • NKSH N/A
  • Revenue Next Year
  • ADAP N/A
  • NKSH $14.93
  • P/E Ratio
  • ADAP N/A
  • NKSH $21.26
  • Revenue Growth
  • ADAP 146.27
  • NKSH N/A
  • 52 Week Low
  • ADAP $0.43
  • NKSH $26.50
  • 52 Week High
  • ADAP $2.05
  • NKSH $35.93
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 37.29
  • NKSH 47.99
  • Support Level
  • ADAP $0.57
  • NKSH $30.80
  • Resistance Level
  • ADAP $0.61
  • NKSH $32.03
  • Average True Range (ATR)
  • ADAP 0.04
  • NKSH 0.87
  • MACD
  • ADAP -0.00
  • NKSH -0.08
  • Stochastic Oscillator
  • ADAP 27.46
  • NKSH 42.01

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.

Share on Social Networks: